Month: January 2025

NEW YORK, Jan. 23, 2025 (GLOBE NEWSWIRE) — Willis, a WTW business (Nasdaq: WTW), is pleased to announce that its Investment Management Insurance (IMI) Plus product is now available to U.S. clients. Previously launched in July 2024 for clients in the UK and Canada, this unified management and professional policy addresses the specific needs of asset managers, providing integrated protection and streamlined management across key risk categories. IMI Plus grants critical coverages—cyber liability, employment practices liability (EPL), directors’ and officers’ (D&O) liability, errors and omissions (E&O) liability, and crime—under one cohesive offering. By consolidating these coverages into one policy, asset managers can reduce administrative complexity while enhancing operational efficiency. The policy’s key benefits include:Multiple...

JENA, Germany, Jan. 23, 2025 (GLOBE NEWSWIRE) — InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that it will participate in the Guggenheim SMID Cap Biotech Conference, to be held February 5 – 6, 2025 in New York, NY. About InflaRx InflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor C5aR. C5a is a powerful inflammatory mediator involved in the progression of a wide variety of inflammatory diseases. InflaRx’s lead product candidate, vilobelimab, is a novel, intravenously delivered, first-in-class,...

News Release January 23, 2025 BioPorto announces the publication of urinary NGAL reference ranges in healthy adult and pediatric individuals COPENHAGEN, DENMARK, January 23, 2025 (GLOBE NEWSWIRE) – BioPorto, an in vitro diagnostics company focused on empowering the early detection of Acute Kidney Injury (AKI), announced today their publication of reference intervals using BioPorto’s NGAL immunoassay in healthy adult and pediatric individuals. The study was published in Diagnostics, an international, open-access, peer-reviewed journal and provides clinicians with a standardized comparison to evaluate NGAL levels ensuring broad clinical applicability in their patients. The publication of the reference range study results will be used by laboratories implementing NGAL assays from BioPorto as a baseline of healthy patient populations, a required...

All amounts expressed in US dollars unless stated otherwise BULYANHULU, Tanzania, Jan. 23, 2025 (GLOBE NEWSWIRE) — Barrick Gold Corporation (NYSE:GOLD) (TSX:ABX) has injected over $4.24 billion into the Tanzanian economy since establishing the Twiga joint venture with the government in 2019, contributing $888 million in 2024 alone. Twiga comprises the North Mara and Bulyanhulu gold mines. At a media briefing here today, Barrick president and chief executive Mark Bristow said the Twiga partnership remained a leader in Tanzania’s extractive industry, creating thousands of jobs, supporting local businesses and funding critical community projects. “We spent $573 million on national suppliers and service providers last year, representing about 83% of our total spend in-country. Additionally, 75% of all our payments to suppliers and...

Rare Urban Environment FAA Waiver Granted to Draganfly for Prescribed Flight Route Over Boston Saskatoon, SK, Jan. 23, 2025 (GLOBE NEWSWIRE) — Draganfly Inc. (NASDAQ: DPRO) (CSE: DPRO) (FSE: 3U8) ‎‎(“Draganfly” or the “Company”), a leader in drone technology and unmanned aerial vehicle (UAV) solutions, an industry-leading drone solutions and systems provider, announced today that it has secured a Federal Aviation Administration (FAA) waiver enabling its small unmanned aircraft (sUA) to conduct operations over human beings and moving vehicles. This waiver marks a significant milestone for Draganfly and highlights its commitment to advancing the capabilities of UAV operations in complex urban environments. The waiver, granted under 14 CFR §§ 107.39—Operations over human beings and 107.145—Operations over moving vehicles, allows Draganfly...